Dupuytren's contracture is a condition in which there is difficulty in articulating fingers due to formation of tissue knots under the skin. In severe conditions, the fingers become permanently bent in a flexed position. Dupuytren's contracture is typically not painful and generally affects the ring finger followed by the little and middle finger. The exact causes of Dupuytren's contracture are unknown however the risk factors include alcoholism, smoking, thyroid problems, liver disease, diabetes, previous hand trauma, epilepsy, family history etc.
The market drivers for Dupuytren’s contracture market are, increase in risk factors rising incomes, growing screening, increasing geriatric population etc. The market restraints are cost of Dupuytren’s contracture surgery, complications and risk of the surgery, invasive nature of treatment, and regression of the disease even after treatment etc.
The global Dupuytren’s contracture market is expected to reach USD 5.5 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.
The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market.
Avail Free Sample at https://www.marketresearchfuture.com/sample_request/4401
Needle aponeurotomy (NA) is the preferred surgical treatment of choice and used in the majority of patients. It is less invasive than the open hand surgery which is now reserved for the most severe conditions. The collagenase injection segment is however expected to grow the fastest due to minimum invasive nature and the lesser hospitalization stay.
Market Key Players:
Key players profiled in the report are –
The global Dupuytren’s contracture market has been segmented on the basis of types, diagnosis, surgery, drugs, therapy and end users.
Based on type, the market has been segmented as type I, type II, type III.
Based on diagnosis, the market has been segmented as physical examination, x-ray and others.
Based on drug, the market has been segmented as steroids, collagenase injection, immune-modulators and others.
Based on therapy, the market has been segmented as radiation therapy, physiotherapy and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research and others.
Intended Audience
Regional Analysis
Europe account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the greater prevalence of Dupuytren’s contracture in Europe drives the Dupuytren’s contracture market. Also, concentration of major research companies in the developed countries of this region is adding fuel to the market growth. The highly developed healthcare system of the Scandavanian region coupled with high expenditure on healthcare, cruises the sale of Dupuytren’s contracture treatment. Europe is led by countries such as Germany and France. Norway is expected to be the fastest growing market.
US is the second largest market in the world due to high income and healthcare penetration. The presence of large healthcare players in the US benefits the market coupled with the high public expenditure on healthcare which comes to be approximately 16 % of the GDP. Asia Pacific region is expected to grow at a slower rate with China and India are likely to lead this market due to fast growing healthcare sector during the forecast period. The lower prevalence of Dupuytren’s contracture in the Asian populations acts as a drag on the market.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The development of large hospitals such as the King Fahd hospital in Riyadh is driving the market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development. Also the lower prevalence of Dupuytren’s contracture in the Asian populations acts as a drag on the market.
Contact: Market Research Future
The market drivers for Dupuytren’s contracture market are, increase in risk factors rising incomes, growing screening, increasing geriatric population etc. The market restraints are cost of Dupuytren’s contracture surgery, complications and risk of the surgery, invasive nature of treatment, and regression of the disease even after treatment etc.
The global Dupuytren’s contracture market is expected to reach USD 5.5 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.
The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market.
Avail Free Sample at https://www.marketresearchfuture.com/sample_request/4401
Needle aponeurotomy (NA) is the preferred surgical treatment of choice and used in the majority of patients. It is less invasive than the open hand surgery which is now reserved for the most severe conditions. The collagenase injection segment is however expected to grow the fastest due to minimum invasive nature and the lesser hospitalization stay.
Market Key Players:
Key players profiled in the report are –
- Bristol-Meyers Squibb Co
- Fresenius Kabi
- Merck & Company
- Pfizer Inc.
- West-Ward Pharmaceuticals
- Spear Pharmacueticals
- Actiza Pharmaceutical Private Limited
- Nantong Jinghua Pharmaceutical Co. Ltd.
- Endo International plc.
The global Dupuytren’s contracture market has been segmented on the basis of types, diagnosis, surgery, drugs, therapy and end users.
Based on type, the market has been segmented as type I, type II, type III.
Based on diagnosis, the market has been segmented as physical examination, x-ray and others.
Based on drug, the market has been segmented as steroids, collagenase injection, immune-modulators and others.
Based on therapy, the market has been segmented as radiation therapy, physiotherapy and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research and others.
Intended Audience
- Global Dupuytren’s contracture treatment manufacturers & suppliers
- Research and development (R&D) companies
- Hospitals and clinics
- Academic institutes and universities
Regional Analysis
Europe account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the greater prevalence of Dupuytren’s contracture in Europe drives the Dupuytren’s contracture market. Also, concentration of major research companies in the developed countries of this region is adding fuel to the market growth. The highly developed healthcare system of the Scandavanian region coupled with high expenditure on healthcare, cruises the sale of Dupuytren’s contracture treatment. Europe is led by countries such as Germany and France. Norway is expected to be the fastest growing market.
US is the second largest market in the world due to high income and healthcare penetration. The presence of large healthcare players in the US benefits the market coupled with the high public expenditure on healthcare which comes to be approximately 16 % of the GDP. Asia Pacific region is expected to grow at a slower rate with China and India are likely to lead this market due to fast growing healthcare sector during the forecast period. The lower prevalence of Dupuytren’s contracture in the Asian populations acts as a drag on the market.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The development of large hospitals such as the King Fahd hospital in Riyadh is driving the market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development. Also the lower prevalence of Dupuytren’s contracture in the Asian populations acts as a drag on the market.
Contact: Market Research Future
Comments
Post a Comment